KMDA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

KM

Volume

38.86K

Next Earnings

November 9th

Loading chart

KM

KMDAKamada Ltd

KMDA

Pay with—

Available Balance0.00

KM

Mkt Cap

$451.9M

Volume

38.86K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Kamada to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceKamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced that CEO Amir London will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The presentation will be webcast and available for 30 days. The company continues to focus on organic growth of its commercial portfolio, plasma collection operations, and pursuing M&A opportunities.GlobeNewswire Inc. · Sep 10, 2026

Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing LaboratoryKamada Ltd. announced FDA approval of its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Beit Kama, Israel. The facility will enhance quality control and testing capabilities for the company's rabies immunoglobulin products KEDRAB and KAMRAB, which generated over $70 million in 2025 sales. The laboratory represents a significant expansion of Kamada's advanced testing capabilities and demonstrates the company's commitment to innovation and operational efficiency.GlobeNewswire Inc. · Jun 1, 2026

Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced it will release its first quarter 2026 financial results on May 13, 2026, followed by a management conference call. The company operates three FDA-approved plasma collection centers in Texas and focuses on growth through its commercial portfolio of specialty plasma products, third-party pharmaceutical distribution, plasma collection operations, and strategic M&A opportunities.GlobeNewswire Inc. · May 6, 2026

Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, TexasKamada Ltd. announced FDA approval of its San Antonio, Texas plasma collection center following an on-site inspection in February 2026. The 11,100 square foot facility has a planned capacity of approximately 50,000 liters per year and is expected to generate $8-10 million in annual revenues from normal source plasma sales at full capacity. The center is anticipated to be one of the largest specialty plasma collection centers in the U.S., complementing Kamada's existing operations in Houston and Beaumont, Texas.GlobeNewswire Inc. · Mar 26, 2026

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability GrowthKamada reported strong financial performance in Q3 2025, with revenues of $47.0 million (up 13% year-over-year) and adjusted EBITDA of $11.7 million (up 34%). The company reiterated its full-year revenue guidance of $178-$182 million and continues to focus on business development and plasma collection operations.GlobeNewswire Inc. · Nov 10, 2025

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025Kamada Ltd. will release its Q3 and nine-month financial results on November 10, 2025, and will host an investment community conference call to discuss the results.GlobeNewswire Inc. · Nov 3, 2025

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025Kamada Ltd., a global biopharmaceutical company, announced that it will release its financial results for the fourth quarter and fiscal year ended December 31, 2024, on March 5, 2025. The company will host an investor conference call to discuss the results.GlobeNewswire Inc. · Feb 26, 2025

Alvotech heldur kynningarfund fyrir fjárfesta 27. mars 2025, eftir birtingu uppgjörs fyrir árið 2024 og fjórða ársfjórðungAlvotech, a biopharmaceutical company, will hold an investor presentation on March 27, 2025, following the release of its Q4 2024 and full-year 2024 financial results. The presentation will be held at the company's headquarters and will be webcast.GlobeNewswire Inc. · Feb 24, 2025

Kamada to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, prior to the open of the U.S. financial markets on Wednesday, May 8, 2024.GlobeNewswire Inc. · May 1, 2024

Kamada Issues 2024 CEO Letter to ShareholdersREHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer.GlobeNewswire Inc. · Mar 6, 2024

to start trading

KM

KMDAKamada Ltd

KMDA

Pay with—

Available Balance0.00

Your PositionYou don't own any KMDA yet.

Related Tickers

Earnings